Idiopathic Pulmonary Fibrosis News and Research

RSS
Pulmonary fibrosi is a condition in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. The development of the scarred tissue is called fibrosis. As the lung tissue becomes thicker, your lungs lose their ability to move oxygen into your bloodstream. As a result, your brain and other organs don't get the oxygen they need.

In some cases, doctors can find out what's causing the fibrosis. But in most cases, they can't find a cause. They call these cases idiopathic pulmonary fibrosis (IPF). IPF is a serious condition. About 200,000 Americans have it. About 50,000 new cases are diagnosed each year. IPF mostly affects people who are 50 to 75 years of age. IPF varies from person to person. In some people, the lung tissue quickly becomes thick and stiff. In others, the process is much slower. In some people, the condition stays the same for years. IPF has no cure yet. Many people live only about 3 to 5 years after diagnosis. The most common cause of death related to IPF is respiratory failure.
Coalition for Pulmonary Fibrosis announces winners of 2012 annual awards for distinguished service

Coalition for Pulmonary Fibrosis announces winners of 2012 annual awards for distinguished service

Enrollment complete in Boehringer Ingelheim’s nintedanib phase III studies for IPF

Enrollment complete in Boehringer Ingelheim’s nintedanib phase III studies for IPF

Boehringer Ingelheim completes enrollment in nintedanib Phase III trials for IPF

Boehringer Ingelheim completes enrollment in nintedanib Phase III trials for IPF

Thalidomide effective in treating disabling cough among people with idiopathic pulmonary fibrosis

Thalidomide effective in treating disabling cough among people with idiopathic pulmonary fibrosis

CPF to kick off 'Pulmonary Fibrosis Awareness Month'

CPF to kick off 'Pulmonary Fibrosis Awareness Month'

New analyses from Esbriet RECAP study in IPF patients presented at ERS 2012

New analyses from Esbriet RECAP study in IPF patients presented at ERS 2012

Boehringer Ingelheim announces data from olodaterol plus tiotropium Phase II COPD study

Boehringer Ingelheim announces data from olodaterol plus tiotropium Phase II COPD study

First data from Boehringer Ingelheim’s Respimat Phase III asthma program

First data from Boehringer Ingelheim’s Respimat Phase III asthma program

FibroGen receives FDA Orphan Drug Designation for FG-3019 to treat IPF

FibroGen receives FDA Orphan Drug Designation for FG-3019 to treat IPF

Results from Boehringer Ingelheim’s Respimat Phase II study on moderate, persistent asthma

Results from Boehringer Ingelheim’s Respimat Phase II study on moderate, persistent asthma

UAB creates Program in Environmental and Translational Medicine

UAB creates Program in Environmental and Translational Medicine

InterMune reaches definitive agreement with Vidara to sell Actimmune

InterMune reaches definitive agreement with Vidara to sell Actimmune

Osteopenia/osteoporosis more prevalent among male patients with pulmonary disease

Osteopenia/osteoporosis more prevalent among male patients with pulmonary disease

Three-drug combo harmful for patients with idiopathic pulmonary fibrosis

Three-drug combo harmful for patients with idiopathic pulmonary fibrosis

Biogen Idec first quarter revenues increase 7% to $1.3 billion

Biogen Idec first quarter revenues increase 7% to $1.3 billion

CPF proclaims September as 'Pulmonary Fibrosis Awareness Month'

CPF proclaims September as 'Pulmonary Fibrosis Awareness Month'

Experts highlight latest advances in use of biomarkers in various diseases

Experts highlight latest advances in use of biomarkers in various diseases

Inhaled interferon-gamma may effectively treat IPF

Inhaled interferon-gamma may effectively treat IPF

DTMI, Bristol-Myers Squibb partner to broaden interactions

DTMI, Bristol-Myers Squibb partner to broaden interactions

IQWiG examines added benefit of pirfenidone for idiopathic pulmonary fibrosis

IQWiG examines added benefit of pirfenidone for idiopathic pulmonary fibrosis

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.